Cognitive function and quality of life in ovarian cancer (Q37957675)

25 August 2017

Cognitive function and quality of life in ovarian cancer (English)

1 reference

25 August 2017

1 reference

1 reference

Denise D Correa

1

1 reference

PubMed ID

22094932

25 August 2017

Lisa M Hess

series ordinal

2

1 reference

PubMed ID

22094932

25 August 2017

language of work or name

English

0 references

publication date

15 November 2011

1 reference

25 August 2017

1 reference

25 August 2017

124

1 reference

25 August 2017

3

1 reference

25 August 2017

404-409

1 reference

Cognitive impairment associated with chemotherapy for cancer: report of a workshop

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Neurocognitive changes in cancer survivors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

7 January 2021

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Primary ovarian cancer chemotherapy: current standards of care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Cognitive function in breast cancer patients receiving adjuvant chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Cognitive function in breast cancer patients prior to adjuvant treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

The interactive effect of the cholinergic system and acute ovarian suppression on the brain: an fMRI study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Is cognitive functioning detrimentally affected after early, induced menopause?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Neurotoxicity secondary to antineoplastic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Candidate mechanisms for chemotherapy-induced cognitive changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Neuropsychological sequelae of non-central nervous system cancer and cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Cognitive functions in long-term survivors of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

A review of issues surrounding quality of life among women with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

A methodological framework for assessing health indices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

On the receiving end—II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Quality of Life of Women with Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Quality of life in ovarian cancer patients receiving chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

The moderating role of negative affect on objective verbal memory performance and subjective memory complaints in healthy older adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Psychometric properties of a new metamemory questionnaire for older adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Subjective complaints compared to the results of neuropsychological assessment in patients with epilepsy: The influence of comorbid depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Neurocognitive profiles in older adults with and without major depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Prevalence and predictors of “subjective cognitive complaints” in the Sydney Memory and Ageing Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada [...]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Fatigue in ovarian carcinoma patients: a neglected issue?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

Assessing cognitive function in cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.005

10.1016/J.YGYNO.2011.11.005

7 January 2021

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22094932